Skip to main content
. Author manuscript; available in PMC: 2012 Apr 22.
Published in final edited form as: Chem Biol. 2011 Apr 22;18(4):531–541. doi: 10.1016/j.chembiol.2010.12.021

Figure 2. Functional characterization of CBP BRD chemical modulators in transcription.

Figure 2

(A) Dose-dependent inhibition of p21 luciferase activity in U2OS cells upon treatment of ischemin or MS119. The luciferase activity was normalized to renilla luciferase as a control. The IC50 was calculated using PRISM software. (B) Effects of the CBP BRD ligands on BRDU incorporation in U2OS cells upon doxorubicin treatment. The data showing that ischemin or MS119 prevents a doxorubicin-induced decrease of BRDU incorporation. See also Figure S2.